MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jtct.2022.12.018

Медицинская библиотека · Transplantation and cellular therapy · 2022

Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.

Webster Jonathan A, Reed Madison, Tsai Hua-Ling, Ambinder Alexander, Jain Tania, Dezern Amy E, Levis Mark J, Showel Margaret M, Prince Gabrielle T, Hourigan Christopher S, Gladstone Douglas E, Bolanos-Meade Javier, Gondek Lukasz P, Ghiaur Gabriel, Dalton W Brian, Paul Suman, Fuchs Ephraim J, Gocke Christian B, Ali Syed Abbas, Huff Carol Ann, Borrello Ivan M, Swinnen Lode, Wagner-Johnston Nina, Ambinder Richard F, Luznik Leo, Gojo Ivana, Smith B Douglas, Varadhan Ravi, Jones Richard J, Imus Philip H

СтатьяПоддержка NIH: внешняя программаПеревод пока не подготовлен

Аннотация

Patients age ≥55 years with acute lymphoblastic leukemia (ALL) fare poorly with conventional chemotherapy, with a 5-year overall survival (OS) of ∼20%. Tyrosine kinase inhibitors and novel B cell-targeted therapies can improve outcomes, but rates of relapse and death in remission remain high. Allogeneic blood or marrow transplantation (alloBMT) provides an alternative consolidation strategy, and post-transplantation cyclophosphamide (PTCy) facilitates HLA-mismatched transplantations with low rates of nonrelapse mortality (NRM) and graft-versus-host disease (GVHD). The transplantation database at Johns Hopkins was queried for patients age ≥55 years who underwent alloBMT for ALL using PTCy. The database included 77 such patients. Most received reduced-intensity conditioning (RIC) (88.3%), were in first complete remission (CR1) (85.7%), and had B-lineage disease (90.9%). For the entire cohort, 5-year relapse-free survival (RFS) and overall survival (OS) were 46% (95% confidence interval [CI], 34% to 57%) and 49% (95% CI, 37% to 60%), respectively. Grade III-IV acute GVHD occurred in only 3% of patients, and chronic GVHD occurred in 13%. In multivariable analysis, myeloablative conditioning led to worse RFS (hazard ratio [HR], 4.65; P = .001), whereas transplantation in CR1 (HR, .30; P = .004) and transplantation for Philadelphia chromosome-positive (Ph+) ALL versus T-ALL (HR, .29; P = .03) were associated with improved RFS. Of the 54 patients who underwent RIC alloBMT in CR1 for B-ALL, the 5-year RFS and OS were 62% (95% CI, 47% to 74%) and 65% (95% CI, 51% to 77%), respectively, with a 5-year relapse incidence of 16% (95% CI, 7% to 27%) and an NRM of 24% (95% CI, 13% to 36%). RIC alloBMT with PTCy in CR1 represents a promising consolidation strategy for B-ALL patients age ≥55 years.

Для цитирования: Webster Jonathan A, Reed Madison, Tsai Hua-Ling, Ambinder Alexander, Jain Tania, Dezern Amy E, Levis Mark J, Showel Margaret M, Prince Gabrielle T, Hourigan Christopher S, Gladstone Douglas E, Bolanos-Meade Javier, Gondek Lukasz P, Ghiaur Gabriel, Dalton W Brian, Paul Suman, Fuchs Ephraim J, Gocke Christian B, Ali Syed Abbas, Huff Carol Ann, Borrello Ivan M, Swinnen Lode, Wagner-Johnston Nina, Ambinder Richard F, Luznik Leo, Gojo Ivana, Smith B Douglas, Varadhan Ravi, Jones Richard J, Imus Philip H. Allogeneic Blood or Marrow Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Acute Lymphoblastic Leukemia in Patients Age ≥55 Years.. Transplantation and cellular therapy. 2022. DOI: 10.1016/j.jtct.2022.12.018.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.